Psychopathology of depression

Drugs of Today

Volumn 43, Issue 10, 2007, Pages 705-716

  Leonard, Brian E ^a,b  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; 4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; 5 HYDROXYINDOLEACETIC ACID; AGOMELATINE; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; AMINE OXIDASE (FLAVIN CONTAINING); AMINOGLUTETHIMIDE; ANTIDEPRESSANT AGENT; ARGIPRESSIN RECEPTOR; BRAIN DERIVED NEUROTROPHIC FACTOR; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; CORTICOTROPIN RELEASING FACTOR RECEPTOR 2; CYTOKINE; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; GLUCOCORTICOID RECEPTOR; GLUTAMIC ACID; HYDROCORTISONE; KETOCONAZOLE; METYRAPONE; MIFEPRISTONE; NORADRENALIN; PRAMPEROLE; PROTIRELIN; PSYCHOSTIMULANT AGENT; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; THYROTROPIN; UNCLASSIFIED DRUG;

BIPOLAR DEPRESSION; CEREBROSPINAL FLUID; CIRCADIAN RHYTHM; DEPRESSION; DOPAMINERGIC SYSTEM; DRUG EFFICACY; DRUG MECHANISM; ELECTROCONVULSIVE THERAPY; ENDOCRINE FUNCTION; GABAERGIC SYSTEM; GENETIC ASSOCIATION; HUMAN; HYPOTHALAMIC PITUITARY THYROID SYSTEM; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMMUNE SYSTEM; MAJOR DEPRESSION; NERVE DEGENERATION; NONHUMAN; PATHOGENESIS; PROTEIN BLOOD LEVEL; REVIEW; RISK ASSESSMENT; SEROTONINERGIC SYSTEM; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANIMALS; DEPRESSIVE DISORDER; DOPAMINE; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; IMMUNE SYSTEM; NOREPINEPHRINE; PITUITARY-ADRENAL SYSTEM; SEROTONIN;

EID: 36849027618     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2007.43.10.1122223     Document Type: Review

References (93)

1. Murray, C.J.L., Lopez, A.D. (Eds). The global burden of disease. Boston, Mass.,Harvard University Press. 1996.
2. Fava, M. Diagnosis and definition of treatment-resistant depression. Biol Psychiat 2003, 53: 649-59.
3. Keller, M.B., Lavori, P.W., Mueller, T.I. et al. Time to recovery, chronicity and levels of psychopathology in major depression. A 5 year prospective follow-up of 431 subjects. Arch Gen Psychiat 1992, 49: 809-16.
4. Sackeim, H.A. The definition and meaning of treatment resistant depression. J clin Psychiat 2001, 62 (Suppl. 16): 10-7.
5. Kennedy, S., McIntyre, R., Fallu, A., Lam, R. Pharmacotherapy to sustain the fully remitted state. J Psychait Neurosci 2002, 27: 269-80.
6. Prange, A.J. The pharmacology and biochemistry of depression. Dis Nerv Syst 1964, 25: 217-21.
7. Schildkraut, J.J. The catecholamine hypothesis of affective disorders: A review of supporting evidence. Am J Psychiat 1965, 122: 509-22.
8. Vetulani, J., Stawarz, R.J., Sulser, F. Adaptive mechanisms of norepinephrine-cAMP generating system in limbic forebrain in the rat:adaptation to persistent changes in the availability of norepinephrine. J Neurochem 1976, 27: 661-6.
9. Hoyer, D., Clarke, D.E., Fozard, J.R. et al. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol Rev 1994, 46: 157-203.
10. Risch, S.C.,Nemeroff, C.B. Neurochemical alterations of serotonergic neuronal systems in depression. J Clin Psychiat 1992, 53 (Suppl. 3-7).
11. Asberg, M., Thoren, P., Traskman, L., Bertilsson, L., Ringberger, V. Serotonin depression- a biochemical subgroup within affective disorders? Science, 1976, 191: 478-80.
12. Mann, J.J., Malone, K.M., Psych, M.R. et al. Attempted suicide characteristics and cerebrospinal fluid amine metabolites in depressed in patients. Neuropsychopharmacol 1996, 15: 576-86.
13. Smith, K.A., Fairburn, C.G., Cowen, P.J. Relapse of depression after rapid depletion of tryptophan. Lancet 1997, 349: 915-9.
14. Booij, L., Van der Does, W., Benkelfat, R. et al. Predictors of mood response to acute tryptophan depletion. A re-analysis. Neuropsychopharmacol 2002, 27: 852-61.
15. Malison, R.T., Price, L.H., Berman, R., van Dyck, C.H. et al. Reduced brain serotonin transporter availability in depression as measured by 1231-2-beta carbomethoxy-3-beta (4-iodophenyl)tropane and single photon emission computed tomography. Biol Psychiat 1998, 44: 1090-8.
16. Perry, E.K., Marshall, E.F., Blessed, G., Tomlinson, B.E., Perry, R.H. Decreased imipramine binding in the brains of patients with depressive illness. BR J Psychiat 1983, 142: 188-92.
17. Stanley, M., Virgilio, J., Gershon, S. Tritiated imipramine binding sites are decreased in the frontal cortex of suicides. Science 1982, 216: 1337-9.
18. Mann, J.J., Huang, Y.Y., Underwood, M.D. et al. A serotonin transporter gene promoter polymorphism (5HTTLPR) and prefrontal cortical binding in major depression and suicide. Arch Gen Psychiat 2000, 57: 729-38.
19. Sen, S., Burmeister, M.,Ghosh, D. Meta-analysis of the association between a serotonin transporter promoter polymorphism (5HTLPR) and anxiety related personality traits. Am J Med Genet B Neuropsychiat Genet 2004, 127: 85-89.
20. Caspi, A., Sugden, K., Moffitt, T.E. et al. Influence of life stress on depression: Moderation by a polymorphism in the 5-HTT gene. Science 2003, 301: 386-9.
21. Kendler, K.S., Kuhn, J.W., Vittum, J., Prescott, C.A., Riley, B. The interaction of stressful events and a serotonin transporter polymorphism in the prediction of episodes of major depression: A replication. Arch Gen Psychiat 2005, 62: 529-35.
22. Kaufman, J., Yang, B.Z., Douglas-Palumberi, H. et al. Social supports and serotonin transporter gene moderate depression in maltreated children. Proc Natl Acad Sci USA 2004, 101: 17316-21.
23. Grabe, H.J., Lamge, M., Wolff, B. et al. Mental and physical distress is modulated by polymorphism in the 5-HT transporter gene interacting with social stressors and chronic disease burden. Mol Psychiat 2005, 10: 220-4.
24. Gillespie, N.A., Whitfield, J.B., Williams, B., Heath, A.C., Martin, N.G. The relationship between stressful life events, the serotonin transporter (5-HTTLPR) genotype and major depression. Psychol Med 2005, 35: 101-11.
25. Hrdina, P.D., Demeter, E., Vu,T.B., Sotonyi, P., Palkovits, M. 5-HT uptake sites and 5-HT2 receptors in brain of antidepressant free suicide victims/depressives: Increase in 5-HT2 sites in cortex and amygdale. Brain Res 1993, 614: 37-44.
26. Bakish, D., Cavazzoni, P., Chudzik, J., Ravindran, A., Hrdina, P.D. Effects of selective serotonin reuptake inhibitors on platelet serotonin parameters in major depressive disorder. Biol Psychiat 1997, 41: 184-90.
27. Meyer, J.H., Kapur, S., Houle, S. et al. Prefrontal cortex 5-HT2 receptors in depression: An 18F-setoperone PET imaging study. Am J Psychiat 1999, 156: 1029-34.
28. Redmond, A.M., Leonard, B.E. An evaluation of the role of the noradrenergic system in the neurobiology of depression: A review. Hum Psychopharmacol 1997, 12: 407-30.
29. Charney, D.S. Monoamine dysfunction and the pathophysiology and treatment of depression. J Clin Psychiat 1998, 59 (Suppl. 14): 11-4.
30. Berman, R.M., Narasimhan, M., Miller,H.L. et al. Transient depressive relapse induced by catecholamine depletion: potential phenotypic vulnerability marker? Arch Gen Psychiat 1999, 56: 395-403.
31. Healy, D., O'Halloran, A., Carney, P.A., Leonard, B.E. Peripheral adrenoceptors and serotonin receptors in depression: Changes associated with treatment with trazodone and amitriptyline. J Affect Dis 1985, 9: 285-96.
32. Moore, R.Y., Bloom, F.E. Central catecholamine neuron systems; anatomy and physiology of the dopamine systems. Ann Rev Neurosci 1978, 1: 129-69.
33. Roy, A., Pickar, D., Douillet, P., Karoum, Finoila, M. Urinary monoamines and monoamine metabolites in subtypes of unipolar depressive disorder and normal controls. Psychol Med 1986, 16: 541-6.
34. Meyer, J.H., Kruger, S., Wilson, A.A. et al. Lower dopamine transporter binding potential in striatum during depression. Neuroreport 2001, 12: 4121-5.
35. Klimek, V., Schenck, J.E., Han, H., Stockmeier, C.A., Ordway, G.A. Dopaminergic abnormalities in amygdaloid nuclei in major depression: a postmortem study. Biol Psychiat 2002, 52: 740-8.
36. Gutman, D.A., Owens, M.J., Nemeroff, C.B. Corticotropin-releasing factor receptor and glucocorticoid receptor antagonists: New approaches to antidepressant treatment. In: Current and Future developments in Psychopharmacology. Den Boer, J.A., George, M.S., ter Horst, G.J. (Eds.) Amsterdam, Benecke, NL 2005.
37. Skelton, K.H., Nemeroff, C.B., Owens, M.J. Spontaneous withdrawal from the triazolobenzodiazepine alprazolam increase cortical corticotrophin- releasing factor mRNA expression. J Neurosci 2004, 24: 9303-12.
38. Arborelius, L., Owens, M.J., Plotsky, P.M., Nemeroff, C.B. The role of corticotrophin-releasing factor in depression and anxiety disorders. J Endocronol 1999, 160: 1-12.
39. Nemeroff, C.B., Owens, M.J., Bissette, G., Andorn, A.C., Stanley, M. Reduced corticotrophin releasing factor binding sites in the frontal cortex of suicide victims. Arch Gen Psychiat 1988, 45: 577-9.
40. Veith, R.C., Lewis, N., Langohr, J.L. et al. Effect of desipramine on cerebrospinal fluid concentration of corticotrophin releasing factor in human subjects. Psychiat Res 1993, 46: 1-8.
41. Raadsheeer, F.C., Hooghendijk, W.T., Stam, F.C., Tilders, F.J., Stanley, M. Increased numbers of CRF expressing neuroins in the hypothalamic paraventricular nucleus of depressed patients. Neuroendocrinol 1994, 60: 436-44.
42. Schatzberg, A.F., Rothchild, A.J., Stahl, J.B. et al. The dexamethasone suppression test: identification of subtypes of depression. Am J Psychiat 1983, 140: 88-91.
43. Posener, J.A., DeBattista, C., Williams, G.H., Chmura Kraemer, H., Kalehzan, B.M., Schatzberg, A.F. 24 hour monitoring of cortisol and corticotrophin secretion in psychotic and non-psychotic major depression. Arch Gen Psychiat 2000, 57: 755-60.
44. Wolkowitz, O.M., Reus, V.I. Treatment of depression with antiglucocorticoid drugs. Psychosomat Med 1999, 61: 698-711.
45. Belanoff, J.K., Flores, B.H., Kalezhan, M., Sund, B., Schatzberg, A.F. Rapid reversal of psychotic depression using mifepristone. J Clin Psychopharmacol 2001, 21: 516-21.
46. Belanoff, J.K., Rothschild, A.J., Cassidy, F. et al. An open label trial of mifepristone for psychotic major depression. Biol Psychiat 2002, 52: 386-92.
47. Aguilera, G., Rabadan-Diehl, C. Vasopressinergic regulation of the hypothalamus-pituitary-adrenal axis: implications for stress adaptation. Regul Pept 2000, 96: 23-9.
48. Ebner, K., Wotjak, C., Landgraf, R., Engelmann, M. A single social defeat experience selectively stimulates the release of oxytocin, but not vasopressin, within the septal brain area of male rats. Brain Res 2000, 872: 87-92.
49. Griebel, G., Simiand, J., Stemmelin, J., Stenberg, R. The vasopressin V1b receptor as a therapeutic target in stress-related disorders. Curr Drug Targets CNS Neurol Dis 2003, 2: 191-200.
50. Griebel, G., Simiand, J., Serredeil-Le Gal, C., Wagnon, J., Pascal, M., Scatton, B. et al. Anxiolytic and antidepressant-like effects of the non peptide vasopressin V1b antagonist SSR 149415, suggest an innovative approach for the treatment of stress related disorder. Proc Natl Acad Sci USA 2002, 99: 6365-70.
51. Serradeil-Le Gal, C., Wagnon, J., Tonnerre, B., Roux, R. et al. An overview of SSR 149415, a selective vasopressin V1b nonpeptide antagonist for the treatment of stress related disorder. CNS Drug Rev 2005, 11: 53-68.
52. Iijima, M., Chaki, S. An arginine vasopressin V1b antagonist SSR 149415 elicits antidepressant-like effects in an olfactory bulbectomy model. Prog Neuropsychopharmac Biol Psychiat 2007, 31,: 622-7.
53. Kelly, J., Wrynn, A., Leonard, B.E. The olfactory bulbectomised rat as a model of depression: An update. Pharmacol Ther 1997, 74: 299-316.
54. Song, C., Leonard, B.E. The olfactory bulbectomised rat as a model of depression. Neurosci Biobehav Rev 2005, 29: 627-47.
55. Banki, C.M., Bissette, G., Aratoi, M., Nemeroff, C.B. Elevation of immunoreactive CSF TRH in depressed patients. Am J Psychiat 1988, 145: 1526-31.
56. Esposito, S., Prange, A.J., Golden, R.N. The thyroid axis and mood disorders: an overview and future prospects. Psychopharmacol Bull 1997, 33: 205-17.
57. Sullivan, G.M., Hatterer, J.A., Herbert, J. et al. Low levels of transthyretin in the CSF of de pressed patients. Am J Psychiat 1999, 156: 710-5.
58. Hatterer, J.A., Herbert, J., Hidaka, C., Roose, S.P., Gorman, J.M. CSF transthyretin in patients with depression. Am J Psychiat 1993, 150: 813-5.
59. Smith, R. The macrophage theory of depression. Med Hypoth 1991, 35: 298-306.
60. Maes, M. Major depression and activation of the inflammatory response. Adv Exp Biol Med 1999, 461: 25-46.
61. Sluzewska, A., Rybakowski, J., Bosmans, E. et al. Indicators of immune activation in major depression. Psychiat Res 1996, 64: 162-7.
62. Meyers, C.A., Valentine, A.D. Neurologic and psychiatric adverse effects of immunological therapy. CNS Drugs 1995, 3: 56-68.
63. Wichers, M.C., Koek, G.H., Robaeys, G. et al. Indoleamine dioxygenase and interferon alpha induced depressive symptoms : A shift in hypothesis from tryptophan depletion. Mol Psychiat 2005, 10: 538-44.
64. Banks, W.A., Kastin, A.J., Ehrensing, C.A. Blood-borne IL-1 alpha is transported across endothelial blood-spinal cord barrier in mice. J Physiol 1994, 479: 257-64.
65. Marshall, P.S. Allergy and depression: a neurochemical threshold model of the relation between the illnesses. Psychol Bull 1993, 113: 23-43.
66. Katon, W., Sullivan, M.D. Depression and chronic medical illness. J Clin Psychiat 1990, 51: 3-11.
67. Song, C., Dinan, T.G., Leonard, B.E. Changes in the immunoglobulins, complement and acute phase proteins in depressed patients and normal controls. J Affect Dis 1994, 30: 283-8.
68. Myint, A.-M., Leonard, B.E., Steinbusch, H., Kim, Y.-K. Th1,Th2, and Th3 cytokine alterations in major depression. J Affect Dis 2005, 88: 169-73.
69. Sheline, Y.I., Wang, P.W., Gado, M.H. et al. Hippocampal atrophy in recurrent major depression. Proc Nat Acad Sci USA 1996, 93: 3908-13.
70. Mayberg, H.S. Positron emission tomography imaging in depression: A neural systems perspective. Neuroimaging Clin N Am 2003, 13: 805-15.
71. Harrison, P.J. The neuropathology of primary mood disorder. Brain 2002, 125: 1428-49.
72. Duman, R.S., Henninger, G.R., Nessler, E.J. A molecular and cellular theory of depression. Arch Gen Psychiat 1997, 54: 597-606.
73. Leonard, B.E., Myint, A.-M. Inflammation and depression: is there a causal connection with dementia? Neurotox Res 2006, 10: 149-60.
74. Myint,A.-M.,Kim, Y.-K., Verkerk, R., Sharpe, S., Steinbusch, H., Leonard, B.E. Kynurenine pathway in major depression: evidence of impaired neuroprotection. J Affect Dis 2007, 98: 143-56.
75. Chen, P.M., Ganguli, B.H., Mulsant, H.de, Kosky, S.H. The temporal relationship between depressive symptoms and dementia: a community based prospective study. Arch Gen Psychiat 1999, 56: 261-6.
76. Green, R.C., Cupples, L.A., Kurz, A., Auerbach, S. et al. Depression as a risk factor for Alzheimer's disease: The MIRAGE study. Arch Neurol 2003, 60: 753-9.
77. Kennedy, S.H., Emsley, R. Placebo controlled trial of agomelatine in the treatment of major depressive disorder. Eur Neuropsychjopharmacol 2006, 16: 93-100.
78. Leonard, B.E. Melatonin receptors and antidepressant strategies. Ir Psychiat 2007, 8: 10-3.
79. Sanacora, G., Gueorguieva, R., Epperson, C.N. et al. Subtype specific alterations of gamma amino butyric acid and glutamate in patients with major depression. Arch Gen Psychiat 2004, 61: 705-13.
80. McEwen, B.S. Stress and hippocampal plasticity. Ann Rev Neurosci 1999, 22: 105-22.
81. Rogoz, Z., Skuza, G., Maj, J., Danysz, W. Synergistic effect of uncompetitive NMDA receptor antagonists in the forced swimming test in rats. Neuropharmacol 2002, 42: 1024-30.
82. Rogoz, Z., Skuza, G., Kusmider, M. et al. Synergistic effect of imipramine and amantadine in the forced swimming test in rats. Behavioural and pharmacokinetic studies. Pol J Pharmacol 2004, 56: 179-85.
83. Li, X., Witkin, J.M., Need, A.B., Skolnick, P. Enhancement of antidepressant potency by a potentiator of AMPA receptors. Cell Mol Neurobiol 2003, 23: 419-30.
84. Berman, R.M., Cappiello, A., Anand, A. et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiat 2000, 47: 351-54.
85. Cryan, J.F., Kaupmann, K. Don't worry, "B" happy: Role for GABA(B) receptors in anxiety and depression. Trends Pharmacol Sci 2005, 26: 36-43.
86. Sanacora, G., Mason, G.F., Rothman, D.L. et al. Reduced cortical GABA concentrations in depressed patients determined by proton magnetic resonance spectroscopy. Arch Gen Psychiat 1999, 56: 1043-7.
87. Brambilla, P., Perez, J., Barale, F., Schettini, G., Soares, J.C. GABAergic dysfunction in mood disorders. Mol Psychiat 2003, 7(Suppl. 1): S721-37.
88. Sanacora, G., Mason, G.F., Rothman, D.L., Krysytal, J.H. Increased occipital cortex GABA concentrations in depressed patients after therapy with SSRI's. Am J Psychiat 2002, 159: 663-5.
89. Culman, J., Unger, T. Central tachykinins: Mediators of defense reaction and stress reaction. Can J Physiol Pharmacol 1995, 73: 885-91.
90. Kramer, M.S., Cutler ,N., Feighner, J. et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 1998, 281: 1640-5.
91. Krishnan, K.R. Clinical experience with substance P receptor antagonists in depression. J Clin Psychiat 2002, 63 (Suppl. 11): 25-9.
92. Herpfer, I., Lieb, K. Substance P receptor antagonists in psychiatry: rationale for development and therapeutic potential. CNS Drugs 2005, 19: 275-93.
93. Millan, M.J. Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacol Ther 2006, 110: 135-370.